



GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

20th May, 2019

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sirs,

Subject: Media release: Q4 & FY17-18

Please find enclosed a press release issued by the Company in respect of financial results for the quarter and year ended March 31, 2019.

This is for your information and record.

Yours faithfully
For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary



PRESS RELEASE

Monday, 20th May 2019, Mumbai

GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter and full year ended March 31, 2019

Revenue growth at 8%, PAT growth at 21%

Board of Directors of the Company recommends a Dividend of Rs. 20 per equity share (versus Rs. 17.50* last year) for the 12 months period ended March 31, 2019

GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the quarter ended 31st March 2019. Revenue for the quarter came in at Rs.751 crores. Profit After Tax at Rs.123 crores recorded a growth of 17%.

The full year reported Revenue was at Rs.3128 crores, a growth of 8% (sales growth of 10%) versus last year. Profit After Tax at Rs.425 crores is higher by 21% against the prior year period.

Commenting on the results, **A. Vaidheesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited** said,

"I am pleased with our overall strong performance for the year. Our new commercial model, with increased focus on our priority brands and a new trade channel strategy is working well. The underlying Sales growth, adjusting for tail-end brand rationalisation and divestments, is a healthy 12%, driven by our priority brands.

7 of GSK's pharma brands feature among the Industry top 50 as at year end. One of the highlights of this year, is the launch of Nucala® (Mepolizumab), a humanised monoclonal antibody which is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.

We continue to maintain our industry leading presence in Vaccines. 7 of GSK Vaccines feature in the Industry Top-20 vaccines list. Our new vaccine, Infanrix Hexa® launched during the year, featured among this list in its first year of launch. This conjugate vaccine helps protect infants against infections caused by diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilis influenzae type b.

A focussed drive to improve operational efficiencies, use of smart technology, cost reduction and a positive product mix has resulted in our EBITDA margin improving by 2 percentage points versus previous year, to 20%."

*Retrospectively adjusted for Bonus issue in Sep 2018

About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com

Media Contacts:

Ransom D'Souza

Vice President Corporate Communications and Government Affairs

Email: ransom.a.dsouza@gsk.com

Tel: +91 22 24959203